Breaking News

EDF Names Jean-Bernard Levy Interim Chairman, CEO
Tweet TWEET

Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs

Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs 
-Bebeau Brings Her Extensive Experience in Managing Cardiac Device Clinical 
Programs to the Tiara™ and Neovasc Reducer™ New Product Programs- 
-New Clinical Initiatives for Tiara and the Neovasc Reducer Targeted for 2014 
and 2015-
TSX Venture Exchange: NVC 
VANCOUVER, May 8, 2014 /CNW/ - Neovasc Inc. (TSXV: NVC) (the 'Company' or 
'Neovasc') today announced that Vicki Bebeau has joined the company in the 
role of Vice President, Clinical Affairs, a newly-created position. Ms. Bebeau 
brings Neovasc more than 18 years of experience in clinical trial planning and 
management at industry leaders St. Jude Medical, Boston Scientific and 
Medtronic. 
"With the ongoing successes of our Tiara™ mitral valve and Neovasc 
Reducer™ programs, Neovasc is preparing to undertake clinical trial 
initiatives for both products," noted Alexei Marko, CEO of Neovasc. "We plan 
to initiate multinational feasibility studies for Tiara in late 2014, and we 
are targeting a 2015 start for the Reducer clinical program needed for an IDE 
approval in the United States." 
Mr. Marko added, "These high potential programs are central to our success and 
we are delighted to have recruited Vicki Bebeau, a highly experienced industry 
veteran, as our head of Clinical Affairs. Ms. Bebeau has held clinical 
positions of increasing responsibility at medical device industry leaders St. 
Jude Medical, Boston Scientific and Medtronic, where she successfully directed 
multinational clinical studies in Canada, the United States, and Europe." 
Neovasc is preparing to begin formal clinical feasibility studies for its 
Tiara device for the transcatheter treatment of mitral valve disease later 
this year. In addition, building on positive results recently reported from 
the Reducer COSIRA trial, Neovasc has initiated design of a US-IDE study to 
support an application for FDA approval of the Reducer. The study is expected 
to begin next year. 
"Neovasc has earned a strong reputation in the industry for their development 
of novel cardiovascular devices addressing major unmet medical needs, and I 
look forward to playing a key role in advancing the clinical programs that are 
central to the clinical and commercial success of the Tiara and Reducer new 
product programs," commented Ms. Bebeau. 
Neovasc intends to continue the expansion of its clinical team and related 
operations to support the Tiara and Reducer product programs. 
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and 
markets products for the rapidly growing cardiovascular marketplace. Its 
products include the Tiara™ technology in development for the transcatheter 
treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of 
refractory angina and a line of advanced biological tissue products that are 
used as key components in third-party medical products including transcatheter 
heart valves. For more information, visit www.neovasc.com 
Statements contained herein that are not based on historical or current fact, 
including without limitation statements containing the words "anticipates," 
"believes," "may," "continues," "estimates," "expects," "forecasts", 
"targets", and "will" and words of similar import, constitute "forward-looking 
statements" within the meaning of the U.S. Private Securities Litigation 
Reform Act of 1995. Such forward looking statements, including the forecasted 
start date for the formal clinical feasibility studies of the Tiara and the 
targeted FDA approval application for the Reducer, involve known and unknown 
risks, uncertainties and other factors that may cause the actual results, 
events or developments to be materially different from any future results, 
events or developments expressed or implied by such forward-looking 
statements. Such factors include, among others, the following: general 
economic and business conditions, both nationally and in the regions in which 
the Company operates; history of losses and lack of and uncertainty of 
revenues, ability to obtain required financing, receipt of regulatory approval 
of product candidates, ability to properly integrate newly acquired 
businesses, technology changes; competition; changes in business strategy or 
development plans; the ability to attract and retain qualified personnel; 
existing governmental regulations and changes in, or the failure to comply 
with, governmental regulations; liability and other claims asserted against 
the Company; and other factors referenced in the Company's filings with 
securities regulators. Although the Company believes that expectations 
conveyed by the forward-looking statements are reasonable based on the 
information available to it on the date such statements were made, no 
assurances can be given as to the future results, approvals or achievements. 
Given these uncertainties, readers are cautioned not to place undue reliance 
on such forward-looking statements. The Company does not assume the obligation 
to update any forward-looking statements except as otherwise required by 
applicable law.
 

SOURCE  Neovasc Inc. 
Corporate Contact: Chris Clark Neovasc Inc. 604 248-4138 cclark@neovasc.com 
U.S. Media & investor Contact: BLL Partners, LLC Barbara Lindheim 212 584-2276  
blindheim@bllbiopartners.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/May2014/08/c7311.html 
CO: Neovasc Inc.
ST: British Columbia
NI: MTC 2575 WNEWS  
-0- May/08/2014 11:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.